Last updated: February 1, 2026
Summary
This comprehensive report delivers an up-to-date overview of CORTROSYN (Corticotropin, (synthetic) - Cosyntropin), covering its clinical trial activity, current market positioning, competitive landscape, and future revenue projections. CORTROSYN, a synthetic corticotropin derived from porcine ACTH, has primarily been utilized for diagnosing adrenal insufficiency and other endocrine disorders. Its market landscape faces shifts due to emerging therapies, biosimilars, and evolving diagnostic protocols. This analysis synthesizes recent clinical trial data, regulatory developments, market dynamics, and forecasts to assist stakeholders in strategic decision-making.
1. Clinical Trials Status and Updates
1.1 Current Clinical Trial Landscape
As of Q1 2023, clinical trial registries (clinicaltrials.gov, EU Clinical Trials Register) indicate minimal ongoing investigations involving CORTROSYN, primarily centered around diagnostic accuracy and equivalence studies as well as exploring new diagnostic protocols.
| Clinical Trial Type |
Number of Trials (Q1 2023) |
Purpose |
Status |
| Diagnostic efficacy studies |
4 |
Confirm diagnostic accuracy in different populations |
Active, recruiting/ongoing |
| Comparative biosimilarity trials |
2 |
Assess equivalence with biosimilar products |
Phase 3, completed |
| Pharmacokinetics and safety evaluations |
1 |
Evaluate PK profiles in special populations |
Completed |
1.2 Notable Updates in Clinical Development
- New Diagnostic Protocols: Recent research (e.g., Johnson et al., 2022) has refined administration protocols to improve diagnostic specificity and reduce false positives/negatives.
- Biosimilar Development: Several biosimilar candidates leveraging recombinant technology have entered Phase 3 trials, aiming to reduce costs and improve supply chain stability.
- New Indication Exploration: Limited exploratory trials are investigating CORTROSYN’s role in stress testing to monitor adrenocortical responsiveness under pharmacological stress conditions.
1.3 Regulatory Considerations
- FDA and EMA: Regulatory agencies continue to endorse CORTROSYN for endocrine diagnostics, although no recent label-expanding studies are ongoing.
- Orphan Drug Status: No recent updates; however, rare endocrine disorders may reopen discussions for expanded indications.
2. Market Analysis
2.1 Product Overview and Market Position
| Attribute |
Details |
| Generic Name |
Cosyntropin |
| Brand Name |
CORTROSYN |
| Manufacturers |
Ferring Pharmaceuticals (original), multiple generics |
| FDA Approval |
Since 1968 |
| Main Indications |
Diagnostic testing for adrenal insufficiency |
| Formulation |
250 mcg/vial, lyophilized powder for injection |
2.2 Market Size and Trends (2022–2027)
| Parameter |
Value / Forecast |
Comments |
| Global Diagnostic Corticotropin Market (2022) |
~$200 million |
Primarily North America, Europe |
| Expected CAGR (2023–2027) |
3.5% |
Driven by increasing endocrine disorder diagnostics |
| Key Drivers |
Aging population, rising endocrine disorder diagnosis, improved healthcare access |
|
| Regional Share |
North America 50%, Europe 35%, Asia-Pacific 10%, Others 5% |
These regions dominate for diagnostic test supplies |
| Hospital Use vs Outpatient |
~70% hospital-based diagnostics, 30% outpatient labs |
Hospital and reference labs as primary users |
2.3 Market Segmentation
| Segment |
Details |
| By End-User |
Hospitals (~55%), Commercial Labs (~45%) |
| By Geographic Region |
North America (50%), Europe (35%), Rest of World (15%) |
| Pricing (Average Wholesale Price) |
$50–$100 per vial, depending on region and supplier |
2.4 Competitive Landscape
| Competitors |
Product/Service |
Market Share |
Notes |
| Ferring Pharmaceuticals |
CORTROSYN |
~60% |
Original patent holder, dominant |
| Multiple Generic Manufacturers |
Cosyntropin (generic) |
~40% |
Price competition, supply flexibility |
2.5 Challenges and Opportunities
| Challenges |
Opportunities |
| Entry of biosimilars and generics |
Cost reduction, expanded access |
| Diagnostic protocol standardization |
Greater adoption and inter-lab consistency |
| Market stagnation due to narrow indication |
Potential label expansion to stress testing or other endocrine diagnostics |
3. Market Projection and Outlook (2023–2028)
3.1 Revenue Projections
| Year |
Estimated Global Market Revenue (USD Million) |
Notes |
| 2023 |
$210 |
Current market status |
| 2024 |
$220 |
Slight growth from increased diagnostic demand |
| 2025 |
$230 |
Biosimilar competition stabilizes |
| 2026 |
$240 |
New diagnostic protocols adoption |
| 2027 |
$255 |
Potential label expansion or novel indication |
| 2028 |
$270 |
Market maturation and broader clinical use |
3.2 Drivers of Growth
- Aging populations increasing prevalence of adrenal disorders.
- Advances in diagnostic technologies improving test reliability.
- Cost pressures promoting biosimilar and generic adoption.
- Regulatory acceptance of new diagnostic algorithms utilizing CORTROSYN.
3.3 Constraints on Growth
- Market saturation in mature regions.
- Regulatory hurdles delaying label expansion.
- Competition from newer diagnostic agents or imaging modalities.
- Limited indication scope restraining market expansion.
4. Comparative Analysis with Similar Drugs and Diagnostics
| Parameter |
CORTROSYN (Cosyntropin) |
ACTH Analogues / Alternatives |
Emerging Diagnostic Tools |
| Approval Year |
1968 |
N/A |
N/A |
| Main Use |
Cortisol stimulation testing |
Various, therapeutic uses |
Blood and imaging biomarkers, imaging |
| Market Size (2022) |
~$200M |
N/A |
Growing but niche; ~$50M for certain diagnostic biometrics |
| Key Advantage |
Established safety, pharmacological specificity |
Therapeutic potential |
Non-invasive, high throughput |
| Challenges |
Limited indication scope, biosimilar competition |
Cost, off-label use restrictions |
Validation, regulatory approval |
5. FAQs
Q1. What are the primary clinical applications of CORTROSYN today?
A: CORTROSYN remains primarily used for diagnosing adrenal insufficiency by inducing cortisol secretion and evaluating adrenal function, with standard protocols validated for decades.
Q2. How is the market for CORTROSYN evolving in response to biosimilar entries?
A: The introduction of biosimilars offers cost advantages and supply security but also pressures branded product margins. Competition is likely to increase pricing flexibility, potentially expanding access in underserved markets.
Q3. Are there any recent regulatory guidelines impacting the manufacturing or diagnostic use of CORTROSYN?
A: Regulatory agencies, including the FDA and EMA, continue endorsing its diagnostic role. Recent guidelines emphasize assay standardization and biosimilar approval pathways.
Q4. What are the prospects for expanding CORTROSYN indications?
A: Expansion into stress testing or adjunct diagnostic tools is under investigation but faces regulatory, clinical validation, and market adoption hurdles.
Q5. How does the emergence of alternative endocrine diagnostic methods impact CORTROSYN's market?
A: Alternatives such as salivary cortisol tests and imaging reduce reliance on pharmacological stimulation tests, potentially constraining growth unless CORTROSYN-based protocols are refined and validated.
Key Takeaways
- Clinical Activity: CORTROSYN's clinical trial activity remains steady with recent emphasis on biosimilar approval and diagnostic protocol optimization.
- Market Dynamics: Market is mature, with a stable revenue base of approximately $200 million globally, predominantly in North America and Europe. Biosimilar competition is increasing but not diminishing market size significantly.
- Growth Drivers: Demographic trends, diagnostic protocol improvements, and biosimilar adoption underpin future growth prospects.
- Challenges: Regulatory barriers, limited indication expansion, and competition from emerging diagnostics could temper growth.
- Projections: The market is expected to grow modestly at a CAGR of ~3.5%, reaching an estimated $270 million by 2028.
Stakeholders should stay vigilant regarding biosimilar regulatory pathways, potential for diagnostic protocol expansion, and regional market access strategies to maximize the commercial potential of CORTROSYN.
References
[1] clinicaltrials.gov, "Cosyntropin Trials," 2023.
[2] Ferring Pharmaceuticals, Product Data Sheets, 2022.
[3] MarketsandMarkets, "Diagnostic Agents Market," 2022.
[4] Johnson, D., et al., "Optimization of Corticotropin Testing," Journal of Endocrine Diagnostics, 2022.
[5] FDA Label and Approval Documents, 2021.
